TauroPharm

TauroPace™ sets a new standard for the prevention of infections from cardiac implantable electronic devices: https://t.ly/ehm7S #tauropharm #tauropace #infectionprevention #cardiology #cardiacsurgery #heartsurgery #pacemaker

From Franconia to Down Under! 🇩🇪 🇦🇺 20 years after TauroLock™ entered the market, taurolidine-based lock solutions are recommended in 𝟯𝟬+ 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 worldwide. 🌎  From 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮, we’ve got several noteworthy publications: 👉 The National Health and Medical Research Council (NHMRC) recommends 𝘁𝗮𝘂𝗿𝗼𝗹𝗶𝗱𝗶𝗻𝗲 𝗳𝗼𝗿 𝗹𝗼𝗰𝗸 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗵𝗮𝗲𝗺𝗼𝗱𝗶𝗮𝗹𝘆𝘀𝗶𝘀 because it has been found to have a “very broad-spectrum antimicrobial activity”, decrease development of biofilms, and be associated with a “reduced CRBSI rate compared to heparin”. (1)  👉 The Government of Western Australia recommends 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™-𝗛𝗘𝗣𝟭𝟬𝟬 𝗳𝗼𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹-𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗰𝗰𝗲𝘀𝘀 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 𝗶𝗻 𝗽𝗮𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 who are at increased risk of developing a CLABSI. In particular, the guideline suggests using the lock solution for primary prevention, stating that it “may be commenced upon insertion of a new CVAD (preferable) or commenced in a child with an existing CVAD”. (2) 💡If you’d like to know more, feel free to reach out to Denish Pashuwala from Prima MediPharm, our exclusive distributor in Australia and New Zealand! #tauropharm #taurolock #taurolidine #dialysis #infectionprevention 1) Australian guidelines for haemodialysis catheters. National Health and Medical Research Council (NHMRC) 2015.   2) TaurolockHep100® prophylactic lock for central venous access devices. Government of Western Australia / Child and Adolescent Health Service 2018. 

From Franconia to Down Under! 🇩🇪 🇦🇺 20 years after TauroLock™ entered the market, taurolidine-based lock solutions are recommended in 𝟯𝟬+ 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 worldwide. 🌎  From 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮, we’ve got several noteworthy publications: 👉 The National Health and Medical Research Council (NHMRC) recommends 𝘁𝗮𝘂𝗿𝗼𝗹𝗶𝗱𝗶𝗻𝗲 𝗳𝗼𝗿 𝗹𝗼𝗰𝗸 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗵𝗮𝗲𝗺𝗼𝗱𝗶𝗮𝗹𝘆𝘀𝗶𝘀 because it has been found to have a “very broad-spectrum antimicrobial activity”, decrease development of biofilms, and be associated with a “reduced CRBSI rate compared to heparin”. (1)  👉 The Government of Western Australia recommends 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™-𝗛𝗘𝗣𝟭𝟬𝟬 𝗳𝗼𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹-𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗰𝗰𝗲𝘀𝘀 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 𝗶𝗻 𝗽𝗮𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 who are at increased risk of developing a CLABSI. In particular, the guideline suggests using the lock solution for primary prevention, stating that it “may be commenced upon insertion of a new CVAD (preferable) or commenced in a child with an existing CVAD”. (2) 💡If you’d like to know more, feel free to reach out to Denish Pashuwala from Prima MediPharm, our exclusive distributor in Australia and New Zealand! #tauropharm #taurolock #taurolidine #dialysis #infectionprevention 1) Australian guidelines for haemodialysis catheters. National Health and Medical Research Council (NHMRC) 2015.   2) TaurolockHep100® prophylactic lock for central venous access devices. Government of Western Australia / Child and Adolescent Health Service 2018. 

𝙎𝙖𝙫𝙞𝙣𝙜 𝙡𝙞𝙫𝙚𝙨 𝙬𝙞𝙩𝙝 𝙡𝙤𝙘𝙠𝙚𝙙 𝙡𝙞𝙣𝙚𝙨 𝘿𝙤𝙬𝙣 𝙐𝙣𝙙𝙚𝙧! 🇦🇺 We are delighted to announce that Prima MediPharm is now the 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿 𝗳𝗼𝗿 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗶𝗻 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮 𝗮𝗻𝗱 𝗡𝗲𝘄 𝗭𝗲𝗮𝗹𝗮𝗻𝗱, with Denish Pashuwala as their Product and Sales Manager. Denish has been a long-standing partner of ours, always working extremely hard, and we only expect him to continue to do so in the future. 🚀 If you’d like to know more about Prima MediPharm, have a look at their brand-new website (link in comments)! 👇

We’re excited to introduce Prima MediPharm, a company committed to providing healthcare professionals with solutions that truly make a difference for patients. Partnering with international manufacturers, we deliver the most innovative technologies across Australia, New Zealand, and the South Pacific. One of the standout products we distribute is TauroLock™, a clinically proven antimicrobial catheter lock. Developed by TauroPharm , TauroLock™ offers Triple Efficacy: Anti-Infection, Anti-Biofilm, and Anti-Occlusion features. We’re thrilled to share our journey with you and look forward to making a sustainable impact in the healthcare space. If you’d like to learn more about Prima MediPharm and our products, please reach out! We’d love to connect and collaborate. Visit our new website to find out more. https://lnkd.in/g2scrFeF #PrimaMediPharm #TauroPharm #TauroLock #VascularAccess #PatientCare #InfectionPrevention #ThrombosisPrevention #CatheterManagement

The countdown to 2025 has begun! Time for a little 𝘤𝘰𝘶𝘯𝘵-𝘶𝘱 of our performance in 2024: 🎉 We started off celebrating 𝟮𝟬 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ , which entered the market in 2004.  💻 We also put 𝟯 𝗻𝗲𝘄 𝘄𝗲𝗯𝘀𝗶𝘁𝗲𝘀 on the map: tauropharm.com, tauropace.com, and the French version of taurolock.com.  📈 On LinkedIn, we published more than 𝟭𝟭𝟬 𝗽𝗼𝘀𝘁𝘀 and hit a milestone with 𝟭,𝟬𝟬𝟬 𝗳𝗼𝗹𝗹𝗼𝘄𝗲𝗿𝘀.   💡 Last but not least, another significant benchmark was the first clinical trial on TauroPace™ receiving more than 𝟭𝟬,𝟬𝟬𝟬 𝘃𝗶𝗲𝘄𝘀.  Of course, our work is more than a numbers game. Those numbers are only the means to an end: They help us 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀, 𝗮𝗻𝗱 𝘂𝗹𝘁𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 – both on- and offline. We were particularly excited to meet so many of you in person throughout the year, from international conventions to workshops at our headquarters.  Our global network keeps on growing, 𝘁𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝘆𝗼𝘂𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁, and we’re excited to see what 2025 has in store for us. 𝙃𝙚𝙧𝙚’𝙨 𝙩𝙤 𝙖𝙣𝙤𝙩𝙝𝙚𝙧 𝙮𝙚𝙖𝙧 𝙤𝙛 𝙨𝙖𝙫𝙞𝙣𝙜 𝙡𝙞𝙫𝙚𝙨 𝙬𝙞𝙩𝙝 𝙡𝙤𝙘𝙠𝙚𝙙 𝙡𝙞𝙣𝙚𝙨 𝙞𝙣 𝟱𝟬+ 𝙘𝙤𝙪𝙣𝙩𝙧𝙞𝙚𝙨!

The countdown to 2025 has begun! Time for a little 𝘤𝘰𝘶𝘯𝘵-𝘶𝘱 of our performance in 2024: 🎉 We started off celebrating 𝟮𝟬 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ , which entered the market in 2004.  💻 We also put 𝟯 𝗻𝗲𝘄 𝘄𝗲𝗯𝘀𝗶𝘁𝗲𝘀 on the map: tauropharm.com, tauropace.com, and the French version of taurolock.com.  📈 On LinkedIn, we published more than 𝟭𝟭𝟬 𝗽𝗼𝘀𝘁𝘀 and hit a milestone with 𝟭,𝟬𝟬𝟬 𝗳𝗼𝗹𝗹𝗼𝘄𝗲𝗿𝘀.   💡 Last but not least, another significant benchmark was the first clinical trial on TauroPace™ receiving more than 𝟭𝟬,𝟬𝟬𝟬 𝘃𝗶𝗲𝘄𝘀.  Of course, our work is more than a numbers game. Those numbers are only the means to an end: They help us 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀, 𝗮𝗻𝗱 𝘂𝗹𝘁𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 – both on- and offline. We were particularly excited to meet so many of you in person throughout the year, from international conventions to workshops at our headquarters.  Our global network keeps on growing, 𝘁𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝘆𝗼𝘂𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁, and we’re excited to see what 2025 has in store for us. 𝙃𝙚𝙧𝙚’𝙨 𝙩𝙤 𝙖𝙣𝙤𝙩𝙝𝙚𝙧 𝙮𝙚𝙖𝙧 𝙤𝙛 𝙨𝙖𝙫𝙞𝙣𝙜 𝙡𝙞𝙫𝙚𝙨 𝙬𝙞𝙩𝙝 𝙡𝙤𝙘𝙠𝙚𝙙 𝙡𝙞𝙣𝙚𝙨 𝙞𝙣 𝟱𝟬+ 𝙘𝙤𝙪𝙣𝙩𝙧𝙞𝙚𝙨!

❓How concerned should we be about 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀? Very, according to recent clinical data. A review published in December 2024 revealed the alarming status quo in 𝗚𝗲𝗿𝗺𝗮𝗻𝘆. (1) The study group analysed data provided by the country’s largest healthcare insurance fund from the year of 2015. Out of 27+ million beneficiaries, they identified a cohort of more than 60,000 patients who underwent an invasive CIED procedure during that period.  ‼️𝟮.𝟲 % 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 (𝟭,𝟱𝟵𝟱 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹) developed a CIED infection within 3 months post procedure.  ‼️The 𝗺𝗼𝗿𝘁𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗲𝘀 amounted to 𝟴.𝟰 % for infections related to generator pockets and 𝟭𝟱.𝟮𝟰 % for infections related to transvenous lead proportions.  What can we do to bring these numbers down? A clinical trial published in 2023 reported that the use of 𝗧𝗮𝘂𝗿𝗼𝗣𝗮𝗰𝗲™ resulted in 𝟬.𝟬𝟬 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 in a cohort of 600+ patients within the 3-month follow-up. (2) 𝙋𝙧𝙚𝙫𝙚𝙣𝙩𝙞𝙤𝙣 𝙞𝙨 𝙗𝙚𝙩𝙩𝙚𝙧 𝙩𝙝𝙖𝙣 𝙘𝙪𝙧𝙚!     1) Baldauf et al. Scientific Reports 2024. DOI: 10.1038/s41598-024-82622-1 2) 2) Borov et al. EP Europace 2023. DOI: 10.1093/europace/euad306 

❓How concerned should we be about 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀? Very, according to recent clinical data. A review published in December 2024 revealed the alarming status quo in 𝗚𝗲𝗿𝗺𝗮𝗻𝘆. (1) The study group analysed data provided by the country’s largest healthcare insurance fund from the year of 2015. Out of 27+ million beneficiaries, they identified a cohort of more than 60,000 patients who underwent an invasive CIED procedure during that period.  ‼️𝟮.𝟲 % 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 (𝟭,𝟱𝟵𝟱 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹) developed a CIED infection within 3 months post procedure.  ‼️The 𝗺𝗼𝗿𝘁𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗲𝘀 amounted to 𝟴.𝟰 % for infections related to generator pockets and 𝟭𝟱.𝟮𝟰 % for infections related to transvenous lead proportions.  What can we do to bring these numbers down? A clinical trial published in 2023 reported that the use of 𝗧𝗮𝘂𝗿𝗼𝗣𝗮𝗰𝗲™ resulted in 𝟬.𝟬𝟬 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 in a cohort of 600+ patients within the 3-month follow-up. (2) 𝙋𝙧𝙚𝙫𝙚𝙣𝙩𝙞𝙤𝙣 𝙞𝙨 𝙗𝙚𝙩𝙩𝙚𝙧 𝙩𝙝𝙖𝙣 𝙘𝙪𝙧𝙚!     1) Baldauf et al. Scientific Reports 2024. DOI: 10.1038/s41598-024-82622-1 2) 2) Borov et al. EP Europace 2023. DOI: 10.1093/europace/euad306 

'Tis the season … to bake TauroLock™-shaped cookies! 🍪🎄 No taurolidine used for this recipe though. 🫡 How do you think our creation turned out? Thank you Tauro-Implant GmbH for the cookie cutters! ✨ #tauropharm #taurolock